	US 12,018,260 B2
	Tunable Reversir™ compounds
Ivan Zlatev, Cambridge, MA (US); Adam Castoreno, Cambridge, MA (US); Martin Maier, Cambridge, MA (US); Vasant Jadhav, Cambridge, MA (US); Jae Kim, Cambridge, MA (US); and Pushkal Garg, Cambridge, MA (US)
Assigned to ALNYLAM PHARMACEUTICALS, INC., Cambridge, MA (US)
Filed by ALNYLAM PHARMACEUTICALS, INC., Cambridge, MA (US)
Filed on Jan. 25, 2022, as Appl. No. 17/583,931.
Application 17/583,931 is a continuation of application No. 16/636,255, abandoned, previously published as PCT/US2018/046904, filed on Aug. 17, 2018.
Claims priority of provisional application 62/546,779, filed on Aug. 17, 2017.
Prior Publication US 2023/0029227 A1, Jan. 26, 2023
Int. Cl. C12N 15/113 (2010.01); A61K 31/702 (2006.01)

CPC C12N 15/113 (2013.01) [A61K 31/702 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3515 (2013.01)]

19 Claims

1. A modified oligonucleotide comprising 8-15 linked nucleotides, wherein at most only three of the nucleotides are high affinity monomers, and wherein the modified oligonucleotide comprises a nucleotide sequence substantially complementary to positions 2-8 of an antisense strand of an siRNA, and one of the high affinity monomers in the modified oligonucleotide is base paired with the 6th nucleotide from the 5′-end of the antisense strand of the siRNA.